These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17173664)

  • 61. Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.
    Levy F
    Behav Brain Funct; 2008 Feb; 4():12. PubMed ID: 18304369
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Guanfacine inhibits interictal epileptiform events and sodium currents in prefrontal cortex pyramidal neurons.
    Pasierski M; Kołba W; Szulczyk B
    Pharmacol Rep; 2023 Apr; 75(2):331-341. PubMed ID: 36800106
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex.
    Arnsten AF
    J Pediatr; 2009 May; 154(5):I-S43. PubMed ID: 20596295
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rat model of attention-deficit hyperactivity disorder exhibits delayed recovery from acute incisional pain due to impaired descending noradrenergic inhibition.
    Suto T; Kato D; Koibuchi I; Arai Y; Ohta J; Hiroki T; Obata H; Saito S
    Sci Rep; 2023 Apr; 13(1):5526. PubMed ID: 37016045
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chronic Stimulation of Alpha-2A-Adrenoceptors With Guanfacine Protects Rodent Prefrontal Cortex Dendritic Spines and Cognition From the Effects of Chronic Stress.
    Hains AB; Yabe Y; Arnsten AF
    Neurobiol Stress; 2015; 2():1-9. PubMed ID: 25664335
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A computational psychiatry approach identifies how alpha-2A noradrenergic agonist Guanfacine affects feature-based reinforcement learning in the macaque.
    Hassani SA; Oemisch M; Balcarras M; Westendorff S; Ardid S; van der Meer MA; Tiesinga P; Womelsdorf T
    Sci Rep; 2017 Jan; 7():40606. PubMed ID: 28091572
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Guanfacine poisoning resulting in transient ST-segment elevation: a case report.
    Hirayama I; Kamijo Y; Abe H; Nonaka M; Yano T; Ishii M; Tominaga Y
    Int J Emerg Med; 2024 Apr; 17(1):60. PubMed ID: 38671356
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Age-related changes in the architecture and biochemical markers levels in motor-related cortical areas of SHR rats-an ADHD animal model.
    Bogdańska-Chomczyk E; Wojtacha P; Tsai ML; Huang ACW; Kozłowska A
    Front Mol Neurosci; 2024; 17():1414457. PubMed ID: 39246601
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An in vitro evaluation of guanfacine as a substrate for P-glycoprotein.
    Gillis NK; Zhu HJ; Markowitz JS
    Neuropsychiatr Dis Treat; 2011; 7():501-5. PubMed ID: 21931492
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Relationship between Neurocircuitry Dysfunctions and Attention Deficit Hyperactivity Disorder: A Review.
    Zhu Y; Yang D; Ji W; Huang T; Xue L; Jiang X; Chen L; Wang F
    Biomed Res Int; 2016; 2016():3821579. PubMed ID: 27689077
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Origins of altered reinforcement effects in ADHD.
    Johansen EB; Killeen PR; Russell VA; Tripp G; Wickens JR; Tannock R; Williams J; Sagvolden T
    Behav Brain Funct; 2009 Feb; 5():7. PubMed ID: 19226460
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder.
    Cruz MP
    P T; 2010 Aug; 35(8):448-51. PubMed ID: 20844694
    [No Abstract]   [Full Text] [Related]  

  • 73. Modulation of attention by noradrenergic alpha2-agents varies according to arousal level.
    Coull JT
    Drug News Perspect; 2001 Feb; 14(1):5-11. PubMed ID: 12819804
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Delayed Signs and Symptoms of Extended Release Guanfacine Overdose in Two Adolescent Patients: Implications of Monitoring on the Psychiatry Unit.
    Mishra S; Shekunov J; Derscheid DJ; Canterbury EA; Leung JG
    Case Rep Psychiatry; 2022; 2022():2149301. PubMed ID: 35371580
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Guanfacine hydrochloride for attention deficit hyperactivity disorder.
    Aust Prescr; 2018 Aug; 41(4):131-132. PubMed ID: 30116086
    [No Abstract]   [Full Text] [Related]  

  • 76. Serotonergic and Adrenergic Neuroreceptor Manipulation Ameliorates Core Symptoms of ADHD through Modulating Dopaminergic Receptors in Spontaneously Hypertensive Rats.
    Madhyastha S; Rao MS; Renno WM
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396978
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anxiety and dysautonomia symptoms in patients with a Na
    de Cássia Collaço R; Lammens M; Blevins C; Rodgers K; Gurau A; Yamauchi S; Kim C; Forrester J; Liu E; Ha J; Mei Y; Boehm C; Wohler E; Sobreira N; Rowe PC; Valle D; Brock MV; Bosmans F
    Clin Auton Res; 2024 Feb; 34(1):191-201. PubMed ID: 38064009
    [TBL] [Abstract][Full Text] [Related]  

  • 78. adgrl3.1-deficient zebrafish show noradrenaline-mediated externalizing behaviors, and altered expression of externalizing disorder-candidate genes, suggesting functional targets for treatment.
    Fontana BD; Reichmann F; Tilley CA; Lavlou P; Shkumatava A; Alnassar N; Hillman C; Karlsson KÆ; Norton WHJ; Parker MO
    Transl Psychiatry; 2023 Oct; 13(1):304. PubMed ID: 37783687
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.